Labcorp Holdings Inc.

Labcorp Holdings Inc.

LH

$353.92

Updated: 04/11/2026, 15:27:46

Market Cap
$28.70B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US

No historical data available

Company Profile

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

USD
NYSE
CEO: Adam H. Schechter
Employees: 71,000
https://www.labcorp.com
Asset Summaries
Latest generated summaries for LH

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
LH-10-k-fy2025.html3.0 MBtext/htmlENFiled 24/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 46 KPI observations

Revenue

N/A

FY — · Reported

Net income

$0.9B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$1.2B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$0.5B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Dx testing services portfolio

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureUnited States: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureEurope: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)Europe: 0.1% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

Revenue exposure by reported geography
FY 2025 share of total net sales. Regional segments are kept as regions rather than falsely allocated to individual countries.
North America
+0.6%
United States
+0.1%
Europe
+0.1%
Other markets
+0.0%

How the business makes money

Company overview

Global lab services leader; ~71,000 employees, ~100 countries, 750M+ tests in 2025; supported >85% of FDA-approved new drugs in 2025

98%
Source evidence
“During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world.”

Two segments: Dx and BLS

Two segments: Dx (routine + specialty testing, 78% of revenue) and BLS (Central Laboratory and ED, 22%)

97%
Source evidence
“The Company is organized under two segments: Dx, which includes routine testing and specialty/esoteric testing; and BLS, consisting of Central Laboratory and ED businesses.”

Two reportable segments: Dx and BLS

Two segments: Dx (diagnostic testing billed to third parties incl. MCOs) and BLS (supports pharmaceutical, biotechnology, and medical device companies)

97%
Source evidence
“both Dx and BLS operate in highly competitive industries and selection of a commercial laboratory or a drug development partner is based on a number of competitive factors”

Diagnostics Laboratories segment

Diagnostics Laboratories (Dx)

90%
Source evidence
“Dx's National Office of Quality, BLS's Global Regulatory Compliance and Quality Assurance Unit”

Biopharma Laboratory Services segment

Biopharma Laboratory Services (BLS), including Central Laboratory

90%
Source evidence
“BLS's Central Laboratory business expanded laboratory management services department”

Dx testing services portfolio

Dx: standard, specialty/esoteric, and health & wellness testing via 2,200+ PSCs, 7,000+ in-office phlebotomists, 90,000+ electronic interfaces

96%
Source evidence
“Dx provides broad patient access through strategically located service sites across the U.S., including more than 2,200 PSCs and more than 7,000 in-office phlebotomists”

Organic/acquisition/currency revenue composition FY2025

Total revenue growth 7.2% = organic 4.4% + acquisitions net of divestitures 2.5% + FX 0.4%

97%
Source evidence
“was primarily due to organic revenue of 4.4%, acquisitions, net of divestitures of 2.5%, and favorable foreign currency translation of 0.4%”

FY2025 revenue by segment

FY2025: Dx $10,876.5 (+7.2%), BLS $3,098.2 (+6.0%), eliminations $(23.0), total $13,951.7 (+7.2% vs $13,008.9 in 2024)

99%
Source evidence
“Dx$10,876.5 $10,144.3 7.2 % BLS3,098.2 2,922.6 6.0 % Intercompany eliminations and other(23.0)(58.0)60.4 % Total$13,951.7 $13,008.9 7.2 %”

2025 revenues by segment and geography

FY2025 revenue $13,951.7M; Dx $10,876.5M (78%, nearly all US); BLS 22% (41% US / 59% international); total: North America 87%, Europe 9%, Other 4%

96%
Source evidence
“During 2025, the Company’s revenues of $13,951.7 million were generated as follows:”

Operations and dependencies

Dependence on third parties for critical supplies/services

Dependent on third parties for transportation, laboratory materials, and specialized animal populations; manufacturers have discontinued or recalled reagents, test kits, instruments

94%
Source evidence
“the Company remains dependent on third parties for critical supplies and services, including transportation, laboratory materials, and specialized animal populations”

Positioning and strategy

SYNLAB minority stake

Acquired minority stake in SYNLAB (European diagnostics leader) in 2025 to advance international strategy

94%
Source evidence
“During 2025, the Company advanced its international strategy through the acquisition of a minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe.”

Capex FY2025 and 2026 plan

Capex $434.5 in 2025 (3.1% of revenues); expected to increase to 4.0% in 2026 incl. LaunchPad initiative

96%
Source evidence
“The Company expects this level of spending to increase in 2026 to 4.0%, primarily in connection with projects to support growth in the Company's core businesses, facility expansion and updates, projects related to its LaunchPad initiative”

Four specialty testing focus areas

Specialty growth focus: oncology, women's health, autoimmune disease, neurology; 2025 launches include Alzheimer's and molecular residual disease tests

95%
Source evidence
“The Company focuses on four primary specialty testing areas that it believes represent significant growth areas: oncology, women’s health, autoimmune disease, and neurology.”

Partner of choice for health systems and labs

Signed or completed 13 health system / regional lab collaboration transactions in 2025; deals must be accretive in year 1, return cost of capital within 3 years

95%
Source evidence
“The Company continues to see a strong pipeline of partnership opportunities and, during 2025, signed or completed 13 collaboration transactions with health systems and local and regional laboratories.”

Cell and gene therapy leadership

Cell & gene therapy: ~2,000 global trials (~20% of biopharma pipelines); expanded Madison, WI lab capacity in 2025

94%
Source evidence
“During 2025, the Company expanded its cell and gene therapy laboratory in Madison, Wisconsin, increasing capacity to support the acceleration in this area”

Risks, financing, and outlook

Revolving credit facility and liquidity

Cash $532.3; $1,000.0 available under revolving credit facility amended June 27, 2025, expiring 2030; interest expense $224.1 (+7.6%)

95%
Source evidence
“the Company had $1,000.0 of available borrowings under its revolving credit facility, which was amended on June 27, 2025 and expires in 2030”

Debt structure

Debt at 12/31/2025: $500.1M short-term/current + $5,084.6M long-term; FY2025 interest expense $224.1M

93%
Source evidence
“Short-term borrowings and current portion of long-term debt500.1 1,000.3 ... Long-term debt5,084.6 5,331.2”

OBBBA impact assessment

OBBBA could reduce insurance coverage and testing utilization; Company currently believes impact would not likely be material; provisions effective through 2028

93%
Source evidence
“the Company could experience a decline in utilization of its diagnostics testing services due to a reduction in overall insurance coverage, which may cause the Company's revenue to decrease. However, the Company currently believes any such reduction would not likely have a material impact”

Consumer-centric and international expansion priorities

Long-term priorities: consumer-centric capabilities (2025 HPV/STI self-collection launch) and international expansion via CDx

92%
Source evidence
“During 2025, the Company further advanced these capabilities by launching nationwide self-collection options for human papillomavirus and sexually transmitted infection testing.”

Fortrea TSA expiration

Fortrea TSA expired June 30, 2025, driving $76.2 decrease in Other, net fees

95%
Source evidence
“primarily due to the TSA expiration resulting in a $76.2 decrease of fees charged to Fortrea for the year ended December 31, 2025”

2023 Fortrea spin-off

Fortrea spun off June 2023

90%
Source evidence
“Spin-offJune 2023 spin-off of Fortrea”

PAMA Medicare reimbursement trajectory

PAMA rate reductions frozen for 2026 and capped at 15% per year for 2027-2029

95%
Source evidence
“PAMA has already reduced Medicare reimbursement rates for many tests, and further reductions are expected, although rate reductions are frozen for 2026 and capped at 15% per year for 2027-2029”

Healthcare fraud/abuse and data privacy compliance emphasis

Compliance program emphasizes fraud/abuse, anti-kickback, privacy, sanctions laws

90%
Source evidence
“the program places special emphasis on those related to healthcare fraud and abuse, anti-kickback and physician self-referral prohibitions, government reimbursement, data privacy, anti-bribery and anti-corruption, anti-human trafficking, and trade sanctions”

Reimbursement/payer-mix risk

Shift toward higher mix of government and MCO payers may adversely affect revenues due to lower reimbursement rates

95%
Source evidence
“A shift toward a higher mix of government and MCO payers may adversely effect revenues due to lower reimbursement rates.”

Technology substitution risk incl. AI and point-of-care testing

Point-of-care testing, home test kits, and application of AI to testing could reduce demand for the Company's laboratory services

93%
Source evidence
“application of AI to testing could reduce demand for the Company's services, or competitors could adopt use of these technologies and derive benefits from them sooner than the Company”

Cybersecurity and IT systems risk

IT/cybersecurity failures and AI/ML regulation are disclosed risks

90%
Source evidence
“a failure in the information technology systems of the Company or newly-acquired businesses, the failure of the Company or its third-party suppliers and vendors to maintain the security of their information technology systems or to protect against cybersecurity incidents”

Customer consolidation and insourcing risk

Customer/supplier consolidation may shift insourcing, pricing, and supply access

90%
Source evidence
“consolidation and convergence of customers, competitors, and suppliers, potentially causing material shifts in insourcing, utilization, pricing, reimbursement, and supply chain access”

Labor/unionization risk

Unionization and labor unrest could interrupt business and increase costs

90%
Source evidence
“business interruption, increased costs, and other adverse effects on the Company's operations due to the unionization of employees, union strikes, work stoppages, general labor unrest”

Talent attraction/retention risk

Talent competition and wage growth may impede hiring/retention

90%
Source evidence
“inability to attract, retain, and develop experienced and qualified personnel, including personnel in key roles and critical positions, due to increased competition for talent, wage growth”

Government reimbursement/coverage policy risk

Reimbursement and coverage policy changes (e.g., PAMA) could materially affect results

90%
Source evidence
“changes in government and third-party payer regulations, reimbursement, or coverage policies ... including the impact of PAMA”

Animal research activism risk

Animal rights activism and animal research restrictions are disclosed risks

85%
Source evidence
“impact on the Company's reputation or business from acts of animal rights activists or potential harm, liability, or operational disruptions arising from, or increased regulations and restrictions, of animal research activities”

Patient payment responsibility / days sales outstanding risk

Rising patient responsibility and payer delays pressure DSO and collections

85%
Source evidence
“failure to maintain the Company's days sales outstanding levels, cash collections (in light of increasing levels of patient responsibility), profitability and/or reimbursement”

Acquisition execution risk

Acquisition integration and synergy realization risk

85%
Source evidence
“inability to achieve the expected benefits and synergies of newly acquired businesses, including due to items not discovered in the due diligence process, and the impact on the Company's cash position, levels of indebtedness, and stock price”

Material exposure graph

United States
Revenue Exposure

North America (nearly all Dx in the US) accounts for 87% of total revenues; Dx revenues were generated almost entirely in the US.

Relevance 90·Dependency 80·Confidence 95
Source evidence
“Nearly all of Dx’s revenues were generated in the U.S.”
MCOs and health insurance payers
Customer Exposure

Diagnostics testing is billed primarily to third-party payers; payer mix shift and reimbursement pressure affect revenue.

Relevance 85·Dependency 80·Confidence 93
Source evidence
“The Company's diagnostic testing services are primarily billed to third parties, including MCOs, employer plans, and other health insurance providers”
Third Party (health plans, MCOs, employer plans)
Revenue Exposure

Third-party payers are the largest Dx payer group at 37% of total revenues.

Relevance 85·Dependency 75·Confidence 95
Source evidence
“Third party37 %— %— %37 %”
Pharmaceutical, biotechnology, and medical device companies
Customer Exposure

BLS revenue depends on pharma/biotech/medtech R&D spending; regulatory changes or cost-control could reduce demand.

Relevance 85·Dependency 75·Confidence 92
Source evidence
“efforts to control drug and device costs, or changes in insurer reimbursement practices, may lead customers to reduce R&D spending, which could adversely affect BLS's business”
Pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs
Revenue Exposure

Biopharma customers generate 22% of total revenue, all within BLS, spanning North America 9%, Europe 9%, and other regions 4%.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“Pharmaceutical, biotechnology, medical device, and diagnostic companies, and CROs9 %9 %4 %22 %”
OBBBA
Regulatory Exposure

OBBBA changes to Medicaid and ACA could reduce insurance coverage and diagnostics testing utilization.

Relevance 85·Dependency 60·Confidence 93
Source evidence
“changes to Medicaid and the ACA, and could lead to revised regulatory requirements and reduced federal funding”
U.S. Protecting Access to Medicare Act (PAMA)
Regulatory Exposure

PAMA-driven changes to reimbursement/coverage for laboratory testing are a leading disclosed risk to revenue.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of PAMA”
PAMA
Regulatory Exposure

PAMA reduces Medicare reimbursement for tests, a direct pricing headwind for Dx.

Relevance 80·Dependency 55·Confidence 95
Source evidence
“PAMA has already reduced Medicare reimbursement rates for many tests, and further reductions are expected”
U.S. Clinical Laboratory Improvement Amendments (CLIA)
Regulatory Exposure

Loss or suspension of licenses under CLIA or Medicare/Medicaid could impair laboratory operations.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“loss or suspension of a license or imposition of fines or penalties under, or future changes in, or interpretations of laws or regulations of CLIA, Medicare, Medicaid”
Managed care organizations (MCOs)
Customer Exposure

Failure to retain MCO business due to strategy or business model changes is a disclosed risk; payer mix shifts affect reimbursement.

Relevance 75·Dependency 60·Confidence 85
Source evidence
“failure to retain or attract business from MCOs as a result of changes in strategy or business models”
Reagents, test kits, and laboratory instruments
Supplier Dependency

Manufacturers' discontinuations or recalls of reagents, test kits, or instruments could impact costs, testing volume, and revenue.

Relevance 70·Dependency 75·Confidence 93
Source evidence
“manufacturers discontinue or recall reagents, test kits, or instruments used by the Company to perform laboratory testing”
Medicare/Medicaid federal healthcare programs
Revenue Exposure

Medicare/Medicaid represents 8% of total revenues, creating government reimbursement and regulatory exposure.

Relevance 70·Dependency 45·Confidence 92
Source evidence
“Medicare and Medicaid8 %— %— %8 %”
Skilled labor competition
Cost Driver

Competition for qualified lab and patient-facing personnel and wage growth could raise costs and disrupt operations.

Relevance 65·Dependency 55·Confidence 90
Source evidence
“as a result of increased competition for talent, wage growth, or other market factors, could lead to strategic and operational challenges”
Patient payment responsibility / consumer-driven health plans
Revenue Exposure

Shift to consumer-driven health plans with higher member cost-sharing increases patient responsibility, pressuring cash collections and DSO.

Relevance 65·Dependency 55·Confidence 85
Source evidence
“the impact of a shift to consumer-driven health plans or plans carrying an increased level of member cost-sharing”
Third-party suppliers and vendors
Supplier Dependency

Changes or disruption in services or supplies provided by third parties, or their termination, could disrupt operations; vendor performance is monitored via quality programs.

Relevance 60·Dependency 55·Confidence 85
Source evidence
“changes or disruption in the provision or transportation of services or supplies provided by third parties; or their termination for failure to follow the Company's performance standards and requirements”
Wage growth
Cost Driver

Wage growth and competition for talent are disclosed factors affecting ability to attract and retain qualified personnel.

Relevance 60·Dependency 50·Confidence 85
Source evidence
“due to increased competition for talent, wage growth, or other market factors beyond the Company's control”
SYNLAB
Customer Exposure

2025 minority-stake investment in SYNLAB supports Labcorp's international specialty diagnostics and CDx expansion strategy.

Relevance 60·Dependency 25·Confidence 90
Source evidence
“During 2025, the Company advanced its international strategy through the acquisition of a minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe.”
Artificial intelligence / machine learning
Technology Dependency

Adverse effects from use of or regulation of AI and machine learning tools are disclosed risks to operations.

Relevance 55·Dependency 40·Confidence 80
Source evidence
“or adverse effects from the use of or regulation of AI and machine learning tools”
Geopolitical events and public health crises
Geopolitical Exposure

Natural disasters, adverse weather, geopolitical events, and public health crises could cause business interruption, supply chain disruption, and higher costs.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“business interruption, receivables impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions or inventory obsolescence, increases in material cost or other operating costs, or other impacts on the business due to natural disasters; adverse weather; geopolitical events; public health crises”
Euro
Currency Exposure

Europe contributes 9% of total revenues and 41% of BLS revenues are international, driving FX translation exposure; 2025 FX translation adjustments were +$231.7M.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“Foreign currency translation adjustments231.7 (217.1)183.1”
Artificial intelligence
Competitive Exposure

AI applied to testing could reduce demand for Labcorp's services or benefit competitors faster.

Relevance 55·Dependency 30·Confidence 90
Source evidence
“application of AI to testing could reduce demand for the Company's services, or competitors could adopt use of these technologies”
Full company information
Latest profile, trading, valuation, and identifier data stored for LH.
Share price
$353.92
Market cap
$28.70B
Exchange
NYSE
Currency
USD
CEO
Adam H. Schechter
Employees
71,000
IPO date
29/03/1990
Beta
0.843
Last dividend
$0.00
Day range
$350.66 – $358.53
52-week range
$244.52 – $371.00
1-day performance
-0.47%
1-year performance
44.74%
Current drawdown (1Y)
-4.60%
CIK
0000920148
CUSIP
504922105
ISIN
US5049221055
Created
07/12/2025, 05:03:25
Last update
04/11/2026, 15:27:46

Track Labcorp Holdings Inc. with an AI analyst

See which prediction-market events move LH, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to LH from your Railway `news_articles` table.

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Zacks Investment Research • STOCK • 08/06/2026, 12:51:19

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Zacks Investment Research • STOCK • 05/06/2026, 12:40:45

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 03/06/2026, 16:22:22

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

PRNewsWire • STOCK • 28/05/2026, 09:00:00

Labcorp (LH) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research • STOCK • 22/05/2026, 15:01:13

Should You Continue to Hold Labcorp Stock in Your Portfolio?

Zacks Investment Research • STOCK • 22/05/2026, 13:31:22

LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up

Zacks Investment Research • STOCK • 30/04/2026, 15:55:21

Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 30/04/2026, 14:41:59

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Zacks Investment Research • STOCK • 30/04/2026, 12:40:36

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

PRNewsWire • STOCK • 30/04/2026, 08:50:00

Wall Street's Insights Into Key Metrics Ahead of Labcorp (LH) Q1 Earnings

Zacks Investment Research • STOCK • 29/04/2026, 12:15:45

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

PRNewsWire • STOCK • 22/04/2026, 09:00:00